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CHARACTERISTICS OF 
PATIENTS SURVIVING 
MORE THAN TEN YEARS 
AFTER CARDIAC 
TRANSPLANTATION 
The clinical status and quality of life of 40 patients who lived or are still alive more 
than 10 years after t ansplantation at our institution were reviewed with the use of 
our transplant database, prospective patient examinations, cardiac catheterization, 
and exercise testing. Patient-perceived health status was determined with use of the 
Nottingham Health Profile and General Well Being examinations. Factors associ- 
ated with longevity were determined by a Cox proportional hazards model. Twenty- 
six patients are alive and 14 have died. The mean age at transplant was 32.4 --. 12 
years and the current age (or age at death) is 46.1 _+ 12.8 years. Actuarial freedom 
from rejection was similar to that of patients urviving less than 10 years (p = 0.8), 
but freedom from all types of infection was less (p = 0.005). Immunosuppressive 
drugs include cyclosporine (11/26 patients), azathioprine (24/26), and prednisone 
(26/26, mean dose 12.7 mg/day). Catheterization hemodynamic data show well- 
preserved graft function at a mean follow-up of 11.7 _ 3.3 years. Graft coronary 
artery disease prevalence is 51.0% __. 8%. Exercise test results are as follows: 
duration 8.7 --. 3.5 minutes (range 2 to 16 minutes), maximum heart rate/expected 
rate 77.3% -- 11% (50% to 92%), maximum systolic blood pressure 171 -+ 23 mm Hg 
(140 to 208 mm Hg), and metabolic equivalents 9.2 _ 2.3 units (5.5 to 12.9 units), 
or about 84% of predicted. Mean score on the General Well Being examination was 
75.3 __ 21.6 (normal). Nottingham Health Profile scores were nearly normal, except 
for in the 50- to 64-year-old age group in categories of mobility, pain, sleep quality, 
and energy level. Causes of death were coronary artery disease in 7 of 14, infection 
in 4 of 14, lymphoma in 1 of 14, and nonlymphoid cancer in 2 of 14. In the Cox 
regression, variables most associated with survival (t > 2.0, multivariate p = 0.0005) 
were age at transplantation (t = 3.26), preoperative duration of illness (t = 13.57), 
postoperative cytomegalovirus infection (t = 2.16), and ejection fraction at 12 
months after operation (t = -2.62). We conclude that cardiac transplantation can 
provide patients with end-stage cardiac failure an acceptable general medical 
condition, functional status, and perceived quality of life well into the second ecade 
after operation. (J TnORAC CARDIOVASC SURG 1995;109:1103-15) 
William M. DeCampli, MD, PhD, Helen Luikart, MS, RN, Sharon Hunt, MD, FACC, 
and Edward B. Stinson, MD, Stanford, Calif. 
C ardiac transplantation has proved to be a reason- able therapeutic option for selected patients with 
end-stage heart failure. This conclusion is supported 
by the favorable survival rate and postoperative 
quality of life of patients who have undergone 
cardiac transplantation, compared with these find- 
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ings in those cases managed medically. 1 Most stud- 
ies that support his conclusion, however, have had 
mean or median follow-up periods of only a few 
years and thus do not provide evidence of the 
clinical status and perceived quality of life in the 
longer run, that is, beyond a decade after operation. 
This limitation is imposed by (1) the relatively low 
10-year survival of patients operated on before 1982 
(approximately 30% at Stanford) and (2) the exis- 
tence of only a very few institutions that performed 
a significant number of transplantation perations 
before 1983. With more than 2000 heart transplant 
operations currently done per year in the United 
States, and an actuarial 10-year survival rate of 
approximately 50%, an understanding of the clinical 
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Table I. Dates of  transplantation 
Case No. 
Living patients 
Date of transplant; Current age 
retransplant (yr) 
Deceased patients 
Date of transplant; Current age 
Case No. retransplant (yr) 
1 7/31/74; 6/30/86 49 
2 4/04/75 45 
3 4/22/76 63 
4 6/13/76 67 
5 11/08/76; /15/87 40 
6 1/25/77; 8/13/92 30 
7 2/08/77 55 
8 5/28/77 45 
9 12/26/77; 8/10/89 35 
10 2/07/78 56 
11 4/23/78 51 
12 8/30/78 35 
13 1/20/79 41 
14 3/30/79 50 
15 10/19/79 34 
16 11/18/79 40 
17 12/17/79 26 
18 12/21/79 40 
19 9/24/80 42 
20 11/23/80 26 
21 12/21/80 30 
22 1/13/81 48 
23 6/25/81 53 
24 6/30/81 49 
25 8/07/81 24 
26 10/04/81 59 
27 1/03/70 63 
28 11/08/71 55 
29 6/10/72 65 
30 5/11/74 59 
31 8/19/74; 10/15/74; 10/13/85 27 
32 8/25/74 59 
33 1/26/75; 02/15/81 62 
34 8/31/76 48 
35 7/10/77 60 
36 11/03/77 64 
37 8/01/78 53 
38 2/13/80 39 
39 5/16/81 30 
40 7/29/81; 2/08/92 28 
status and perceived quality of life more than a 
decade after operation is of obvious pertinence. 
In this paper we present results of a study of 40 
patients who are alive or who lived longer than 10 
years after cardiac transplantation at a single insti- 
tution. Specifically, we tested the following hypoth- 
eses about these long-term survivors: (1) the prev- 
alence of graft coronary artery disease (CAD) 
continues to increase with time and graft CAD is a 
significant source of  mortality for this group of 
patients, (2) graft function is well-preserved beyond 
10 years after transplantation, and (3) the exercise 
capacity of these patients and sense of  well-being 
are reasonably close to those of the age-matched 
population at large. 
Finally, we present a derivation of clinical factors 
that correlate with longer-term survival in our insti- 
tution's total transplantation experience. 
Patients and methods 
The preoperative clinical status and postoperative clin- 
ical course (including regular follow-up history, physical 
examination, laboratory values, cardiac biopsy results, and 
cardiac catheterization data) of all patients undergoing 
heart transplantation at Stanford since 1970 were exam- 
ined with the assistance of a database updated to January 
1, 1992. The subset of patients who survived more than 10 
years after their f st heart transplant operation was 
examined in detail. Of the 661 patients in the database, 40 
patients fell into this subset: 26 of these patients were alive 
and 14 had died. Seven of the 40 patients underwent 
cardiac retransplantation. All but two of these received 
retransplantation more than 10 years after the original 
operation. One patient had undergone r transplantation 
twice. The patients and their dates of transplantation are 
listed in Table I. 
The current clinical status of the living patients was 
further determined either at Stanford or by review of 
records of the patient's primary cardiologist. The evalua- 
tion included a review of active and past medical prob- 
lems, current medications, family and social history (in- 
cluding smoking, drinking, and job or marital status 
change since transplantation), physical examination (in- 
cluding current weight), laboratory values (including he- 
matocrit, blood urea nitrogen, creatinine, fasting glucose, 
total cholesterol, triglycerides), and data from all available 
cardiac catheterization reports. Graft CAD was assessed 
either angiographically or at autopsy. The incidence was 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 109, Number 6 
DeCampli  et al. 1 10 5 
determined only for CAD occurring in first-time allografts 
(that is, CAD in a second allograft was not considered). 
Actuarial freedom from CAD was calculated and com- 
pared with that in the set of all other patients who 
underwent ransplantation at this institution. Infection 
and acute rejection data were obtained from the database. 
Presence of acute rejection was noted when a cardiac 
biopsy specimen showed International Society of Heart 
and Lung Transplantation grade II or higher. 
So that functional status could be assessed, exercise 
tests were done on available patients. The actual exercise 
protocol varied for each patient; however, a "maximal" 
test was completed and maximum heart rate, blood pres- 
sure, duration, and exercise capacity (expressed in meta- 
bolic equivalents [METS] standardized for each exercise 
protocol) were determined. Results were compared with 
those of an age-matched sample of the normal population 
and with those of an age-matched cohort of patients who 
underwent transplantation a  average of 7 months before 
evaluation. 
So that we could evaluate patient-perceived health 
status or "sense of well-being," each patient in the subset 
completed both part I of the Nottingham Health Profile 
(NHP) and the General Well Being (GWB) examinations. 
The NHP examination is purported to evaluate "per- 
ceived distress. ''2' 3 The higher the score (0 to 100 for each 
of six sections), the more the distress. Weightings derived 
from the application by McKenna, Hunt, and McEwen 4 of 
Thurstone's method of paired comparisons to the British 
population were applied to each question in the NHP 
survey. The GWB examination is best described as reflect- 
ing "expressions of psychiatric states of depression and 
anxiety or the absence thereof," according to Fazio. 5 
Scores from both tests were compared with those of 
gender-matched norms. Correlations published age and 6
were calculated among the NHP and GWB scores, tread- 
mill performance, employment and marital status, and 
number of current medical problems. 
Because we were interested in factors that might con- 
tribute to (or at least be correlated with)the longevity of 
this subset of patients, two comparison groups were 
formed from the set of all patients who underwent trans- 
plantation at Stanford: (1) patients who survived 0.5 to 5.0 
years after transplantation a d (2) patients who survived 5
to 10 years after transplantation. The age at the time of 
transplantation; actuarial rates of freedom from acute 
rejection and from viral, bacterial, protozoal, and fungal 
infection; and cause of death were determined for each 
group and compared. 
Finally, a formal multivariate analysis was done to 
further clarify the possible factors. Twenty-one variables 
were cited as possibly predictive of longevity. Variables 
evaluated at the time of transplantation included uration 
of preoperative illness, age at the time of transplantation, 
race, gender, hospital ength of stay, number of human 
leukocyte antigen mismatches, erum creatinine level at 
the time of discharge, diastolic blood pressure at the time 
of discharge, donor age, donor race, donor gender, donor 
cytomegalovirus (CMV) status, and recipient CMV status. 
Variables evaluated at 1 year after operation included 
blood urea nitrogen, serum creatinine, diastolic blood 
pressure, left ventricular ejection fraction, degree of 
CAD (quantitated by the number of vessels with signifi- 
cant stenoses), number of acute rejection episodes, num- 
ber of episodes of infection, and incidences of CMV 
infection (as determined by the presence of inclusion 
bodies in tissue, positive culture, or greater than fourfold 
rise in anti-CMV immunoglobulin G serologic titer). 
Univariate analysis of variance was performed for each 
variable from the aforementioned three groups to obtain 
a qualitative estimate of significance. The nine most 
significant variables were determined. The set of all 
patients who underwent transplantation at this institution 
was then chosen and a subset determined that consisted of 
patients each meeting all of the following three criteria: 
(1) survival at least 1 year after operation, (2) not having 
retransplantation, and (3) having no missing data among 
the nine variables. By including only patients who survived 
at least i year, we eliminated operative and early postop- 
erative complications and early refractory rejection and 
infection as causes of mortality. The final subset, consist- 
ing of 122 cases, was used in the multivariate analysis (see 
following section). 
Results are expressed as mean plus or minus the 
standard eviation, unless otherwise specified. Comparii- 
son of means was made by one-way analysis of variance or 
Student's t test. The Fisher exact est was used for nominal 
data in the analysis of the subset of patients receiving 
cyclosporine (n = 8), and the Mann-Whitney U test was 
used to compare variables between patients with and 
without evidence of CAD. Actuarial calculations were 
made with use of the product limit estimator with Green- 
wood's standard error. 7 Comparison of actuarial curves 
was made by the Cox-Mantel test. Correlations were 
examined by determining Pearson coefficients or Spear- 
man rank correlation coefficients. A value ofp < 0.05 was 
considered significant. The multivariate analysis was done 
by the stepwise proportional hazards method of Cox. 8 A 
test of parallelism was made to ensure that the final 
covariates induced proportional (parallel) shifts of the 
arbitrary hazard function. A X 2 statistic was used to test 
the hypothesis that the gradient of the log-likelihood 
function was zero at its initial value, and p < 0.05 was 
considered significant. The relative risk of death caused by 
an increase by m units in a covariate was calculated as exp 
(rob), where b is the estimate of the normalized coeffi- 
cient. Ninety-five percent confidence limits of the relative 
risk are given. 
Henceforth the expression most recent refers to the 
most recently determined value of a variable in living 
patients or the last-determined value before death in 
deceased patients. 
Results 
Dates of transplantation and retransplantation for 
the group of patients surviving longer than 10 years 
are shown in Table I. The majority (32/40) under- 
went transplantation before the introduction of cy- 
closporine into our program in December 1980. 
Basic demographic data are listed in Table II. In 
comparison with patients in the short survival (0.5 to 
5 years) group, the patients in the group with more 
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Table II. Demographic characteristics* 
Item Mean SD Range 
Age at transplant (yr) 32.4 11.7 13-51 
Current age (yr) 46.1 12.8 24-67 
Postop. years 13.7 2.5 11-22 
Admission weight (kg) 65.8 11.4 43-92 
Current weight (kg) 77.9 13.8 49-107 
SD, Standard eviation. 
*Sex: male, 35; female, 5. 
than 10-year survival received transplantation at a 
younger mean age. In the former group, only 15 of 
119 patients were younger than 30 years old at 
operation versus 18 of 40 for the long-term survivors 
(p < 0.001). 
Actuarial freedom from acute rejection, in com- 
parison with that of the two comparison groups, is 
plotted in Fig. 1. These curves are not significantly 
different and reflect the fact that by 0.5 years after 
operation only 15% of patients are free from at least 
one rejection episode. The mean number of infec- 
tious episodes was 2.24 _+ 2.1. The actuarial freedom 
from such events, plotted for each of four major 
pathogen groups, is shown in Fig. 2. In each of the 
four pathogen categories, the long-term survivors 
had significantly greater freedom from infection 
compared with patients in the 0.5- to 5-year (p < 
0.005) and 5- to 10-year (p < 0.05) comparison 
groups. Similarly, when analyzed according to loca- 
tion of infection, the most significant difference 
favoring long-term survivors was found in the inci- 
dence of pneumonia. This fact is consistent with the 
fact that, when infection was the ultimate cause of 
death, the lungs were the most common primary site 
of infection. 
The patients take an average of 6.6 _ 2.7 medi- 
cations per day (range 3 to 14). All patients take 
prednisone at a mean dose of 12.7 + 3 mg/day, and 
nearly all are taking azathioprine. Patients who 
underwent transplantation or retransplantation af-
ter December 1, 1980, are taking cyclosporine. 
Other common medications include a variety of 
antihypertensive drugs, diuretics, prophylactic anti- 
biotics, and antiplatelet agents. Disorders possibly 
attributable to corticosteroid usage include hyper- 
tension (55%), osteoporosis (35%), cataracts 
(27%), cushingoid appearance (26%), diabetes mel- 
litus (24%), and weight gain (19.8 _+ 17.8 kg). Other 
chronic medical problems include seven cases of 
chronic renal insufficiency, 20 cases of graft CAD, 
and 27 noted miscellaneous problems (many attrib- 
utable to adverse ffects of medications). 
Most recent laboratory values for the patients are 
shown in Table III. Of the eight patients with serum 
creatinine values higher than 1.8 mg/dl, seven were 
taking cyclosporine and four of these seven had 
undergone retransplantation. These values are sig- 
nificantly higher than one would expect if the eight 
patients were a random subset of the group (Fisher's 
exact est, p < 0.01). The mean total cholesterol and 
triglyceride values are influenced by one patient 
with isolated hypertriglyceridemia (most recent 
measurement 468 mg/dl) and by two patients with 
combined isorders (cholesterol 445 and 293 mg/dl, 
triglycerides 273 and 298 mg/dl, respectively). For 
five patients evaluated in the retransplantation sub- 
group, values significantly higher than those in the 
first-time transplantation subgroup included blood 
urea nitrogen (36.0 _+ 7.9 mg/dl, p = 0.01), creati- 
nine (2.0 _ 0.27 mg/dl, p = 0.002), and total 
cholesterol (257.2 + 33.7 mg/dl, p = 0.02). 
The most recent cardiac catheterization data, 
obtained at a mean of 11.7 _+ 3.3 years after 
operation, are displayed in Table IV. A remarkable 
feature is the relatively normal hemodynamic data, 
indicating, on average, well-preserved graft function 
at this long follow-up interval. Aortic diastolic pres- 
sure and left ventricular end-diastolic pressure were 
mildly elevated. The prevalence of CAD was 
51.0% + 8.0% (standard error of the estimate) at a 
mean of 11.7 _+ 3.3 years of angiographic or autopsy 
follow-up. For each patient, we determined the 
earliest postoperative time in which angiographic 
evidence of graft CAD was detected: this mean 
value was 9.3 _+ 4.1 years (n = 40). The actuarial 
freedom from CAD for the study group is shown in 
Fig. 3 together with that for all other patients who 
underwent transplantation at Stanford. These two 
curves are not statistically significantly different. 
Values for number of acute rejection episodes, 
aortic diastolic pressure, serum cholesterol, current 
age, current weight, left ventricular end-diastolic 
pressure, and NHP score were not significantly 
different between the subgroups of patients with and 
without evidence of CAD. 
Fourteen of 26 living patients underwent maximal 
exercise testing within 1 year of the current evalua- 
tion. The mean age of this subset was 41.8 years. The 
results are shown in Table V. Patients with heart 
failure or poor overall medical condition tended to 
refuse the test and thus the results are biased on the 
high side. One test was stopped because of electro- 
cardiographic evidence of ischemia nd the remain- 
der were patient-terminated because of fatigue. 
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Fig. 1. Kaplan-Meier actuarial freedom from acute rejection episodes for long-term survivors versus less 
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Fig. 2. Kaplan-Meier actuarial freedom from bacterial, fungal, viral, and protozoal infections for 
long-term survivors. 
There was a significant correlation between METS 
performed and cardiac index on most recent cardiac 
catheterization (Spearman coefficient 0.81, p = 
0.02). 
Twenty-seven patients completed the GWB and 
NHP examinations. The average GWB score was 75.3 
+ 21.6, which is nearly identical to the male normal 
population mean of 75.1 _+ 14.8 (n = 79, mean age 
19.6 years). Because scores for part I of the NHP 
examination could only be properly compared with the 
use of nonparametric statistics (ranks), a formal anal- 
ysis could not be done here. The trends did seem to 
point to higher scores for the patients undergoing 
transplantation, especially in the oldest age group (50 
to 64 years) and subdivisions of mobility, pain, sleep 
quality, and energy level. NHP scores correlated well 
with GWB scores (Pearson R = -0.79). We could not 
find significant correlations between the GWB or 
NHP subdivision scores and variables uch as number 
of current medical problems, complications ofcortico- 
steroids, or performance on the exercise test. Twenty 
percent of patients currently smoke, 52% are currently 
employed, 73% have changed jobs since transplanta- 
tion, 37% have had a change in marital status since 
transplantation, and 38% report some sexual dysfunc- 
tion. 
The actuarial survival curve for the group is 
shown in Fig. 4, together with the analogous curve 
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Table IlL Most recent laboratory values (n = 30) 
Item Value SD Range 
Hematocrit 42.0 4.0 34-48 
Glucose (mg/dl) 109.7 44.4 59-257 
Urea nitrogen (mg/dl) 23.8 12.3 6-51 
Creatinine (mg/dl) 1.4 0.54 0.6-2.8 
Total cholesterol (mg/dl) 224.2 68.9 109-445 
Total triglycerides (mg/dl) 173.4 124.8 58-468 
SD, Standard eviation. 
for all patients who received transplantation at this 
institution (evaluated on March 1, 1994). The causes 
of death for the 14 patients who died are displayed 
in Fig. 5, along with those of patients in the com- 
parison group who survived 0.5 to 5 years. These 
data include the three patients undergoing retrans- 
plantation who died. The predominant cause of 
death was CAD in the long-term survivors, with no 
deaths attributable to complications of acute graft 
rejection. In the short-term survivors, rejection and 
infection play a dominant role in mortality. 
Results of the multivariate analysis of survival are 
listed in Table VI. The four variables found to be 
independently correlated with death after transplan- 
tation were age at transplantation, preoperative 
duration of illness, evidence of postoperative CMV 
infection, and ejection fraction at 12 months after 
operation. The relative risk of death associated with 
an increase of 5 years in the duration of illness was 
1.53 (1.21, 1.93). An increase of 5 years in the age at 
transplantation carried a relative risk of 1.28 (1.10, 
1.48). A decrease in the ejection fraction at 12 
months of 0.1 resulted in a relative risk of death of 
1.51 (1.10, 2.06). History of postoperative CMV 
infection approximately doubled the risk of death 
(1.07, 3.96). As an independent test of the risk 
associated with CMV infection, life-table calcula- 
tions using the product limit estimator on the set of 
all patients undergoing transplantation at this insti- 
tution were stratified by presence or absence of 
evidence of postoperative CMV infection. The 
probability of death within 6 years after operation 
was 26.7% without CMV infection and 46.0% with 
CMV infection, a relative risk of 1.72 (1.20, 2.24). 
Discussion 
Although justification of cardia c transplantation 
as an effective treatment for end-stage heart failure 
is provided by prolonged (>2 year) survival and 
improved functional status, the argument in its favor 
is greatly strengthened by demonstration of the 
Table IV. Most recent cardiac catheterization data 
(n = 26) 
Item Mean SD Range 
Pressures (ram Hg) 
Aortic systolic 124.8 19.5 93-175 
Aortic diastolic 85.2 13.3 62-115 
RA 5.5 2.0 2-9 
PAM 16.1 7.4 9-37 
PAW 9.9 5.6 3-28 
LVED 12.8 6.1 5-25 
Heart rate (beats/rain) 86.4 12.0 67-102 
CI (L/rain per square 2.9 0.57 2.]-4.0 
meter) 
SD, Standard eviation;/CA, right atrial, PAM,, pulmonary arterial mean; 
PA W, pulmonary arterial wedge; L VEDP, left ventricular end-diastolic; CI,
cardiac index. 
possibility of longer-term survival with sustained 
acceptable functional status. This demonstration 
was precisely how the current importance of renal 
transplantation was established 15 years ago. It is 
appropriate, therefore, to discuss our results in the 
context of this paradigm. 
General medical condition. Aside from rejection 
and graft CAD, most of the aforementioned medical 
problems een in our transplant recipients are prob- 
ably complications of immunosuppressive therapy. 
Divakar and colleagues 9 found a similar variety and 
incidence of problems in a group of 36 patients 
surviving reater than 10 years after renal transplan- 
tation. The specific role that corticosteroid usage 
plays in these problems has led many programs to 
use corticosteroid-free maintenance immunosup- 
pression. Initial results of this regimen are encour- 
aging,10, n although the regimen is not feasible in 
many patients. We found that the incidence of 
chronic renal insufficiency was highly correlated to 
the use of cyclosporine in our group. This problem 
still remains, although trials using "low-dose" cyclo- 
sporine 12 and cyclosporine analogs uch as FK 506 
may hold some promise. The incidence of infection 
in our long-term group was remarkably low relative 
to that in the two comparison groups, an observation 
consistent with the fact that infection is a major 
cause of early death with immunosuppressive th r- 
apy. The fact that the curves of actuarial freedom 
from acute rejection in this group and both compar- 
ison groups were all nearly identical means, how- 
ever, that other factors influenced the group's sus- 
ceptibility to early fatal infection, such as differences 
in severity or frequency of rejection or exposure to 
pathogens, degree of augmentation of immunosup- 
pressive drugs, or individual differences in the de- 
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Fig. 3. Kaplan-Meier actuarial freedom from graft CAD for long-term survivors versus all other patients 
who received transplantation at our institution, updated to January 1994. Prob., Probability. 
gree to which given doses of immunosuppressive 
drugs influence the host response to pathogens. 
Graft function. The present work demonstrates, 
for the first time, preserved graft function well into 
the second decade after transplantation. Von 
Scheidt and associates 13 found no evidence of sys- 
tolic dysfunction or dilated or restrictive cardiomy- 
opathy in 71 patients followed up to 7 years after 
operation. Tischler and associates 14 demonstrated 
mild increases in left ventricular end-systolic and 
end-diastolic volumes, but no significant change in 
left ventricular mass or ejection fraction in 22 pa- 
tients doing well and followed up a mean of 4 years 
after operation. Frist and colleagues, 15 in a study of 
174 patients with a mean age of 36 years and 
follow-up period of 5 years, found no deterioration 
in graft hemodynamics. Mean cardiac index and left 
ventricular end-diastolic pressure were almost iden- 
tical to those in the present group. 
Exercise tolerance. Although the exercise tests 
described in this paper were not standardized to a 
particular protocol, certain points can be made. 
First, maximum heart rate and systolic blood pres- 
sure were lower than those of a closely age-matched 
sample of the normal population (p < 0.001), 16 but 
were similar to those of an age-matched group of 
transplant recipients evaluated a mean of 7 months 
after operation in a study by Kavanagh and asso- 
ciates, t7 These results may be explained by the 
failure of the graft o regain sympathetic innervation 
a mean of 12 years after implantation. Second, when 
each patient's estimated maximal oxygen consump- 
Table V. Exercise test results (n = 14) 
Item Mean SD Range 
Duration (rain) 8.7 3.5 2.0-16.3 
Max. HR (beats/rain) 136.0 22.0 86-155 
Percent max. HR* 77.3 11.3 50-92 
Max. systolic BP (mm Hg) 171.4 22.7 140-208 
METS 9.2 2.34 5.5-12.9 
SD, Standard deviation; max., maximum; HR, heart rate; BP, Blood 
pressure. 
*Maximum heart rate = 220 - age in years. 
tion (expressed in METS) is compared with the 
mean value from an age-matched group of normal 
subjects not having transplantation, the group per- 
formed an average of 1.19 + 0.60 (SEM*) METS 
less (p = 0.08) than normal subjects as determined 
by Bruce, Kusumi, and Hosmer 18 and 2.55 _+ 0.65 
(SEM) METS less (p = 0.002) than normal subjects 
as published more recently by Morris and col- 
leagues. 19 These results correspond to an exercise 
capacity of 88% --- 6% and 79% -+ 6% of normal, 
respectively. Yet the group's mean performance was 
substantially better than the average of 6.2 +__ 1.3 
METS performed in the group of transplant recip- 
ients at 7 months after operation in the report of 
Kavanagh and associatesF A possible interpreta- 
tion of these data is that exercise capacity improves 
with duration after operation, which is a hypothesis 
that could be better tested by a longitudinal study. 
Alternatively, the data may indicate a time-related 
*Standard error of the mean. 
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surviving only up to 5 years after transplantation. 
bias in patient selection. The cause of the remaining 
decrement in exercise capacity at 12 years after 
operation is uncertain, 2°but it may be compensated 
for, as Kavanagh and associates 17demonstrated, by
an exercise training program. 
Graft CAD. The most remarkable finding from 
the angiographic data is that this group of long-term 
survivors does not escape graft CAD. In fact, the 
actuarial incidence during the first 10 years after 
operation is similar to that of the transplant popu- 
lation as a whole. Furthermore, the data indicate 
that by 20 years after operation essentially all pa- 
tients can be expected to have graft CAD identifi- 
able by conventional ngiographic techniques. The 
comparison between our group and the overall 
transplant population is made with some reserva- 
tion; that is, because the overall transplant popula- 
tion is right-censored by death in the first 10 years, 
its actuarial prevalence of CAD will be underesti- 
mated relative to the estimate for our group. Studies 
that have attempted to determine risk factors for 
development of graft CAD give inconsistent re- 
sults, 21-29 and the reported prevalence of CAD 
varies widely. 27'3°-32 Indeed, we were unable to 
associate any variables with the presence of CAD in 
our small group of patients. 
Psychosocial evaluation and perceived quality of 
life. In previous, shorter-term studies in this cate- 
gory, the principal findings were (1) overall sense of 
well-being improves after transplantation relative to 
the preoperative state, 33-35 (2) on the average, there 
is no deterioration ofquality of life with time, 33' 3s, 36 
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(3) perceived quality does not correlate significantly 
with medical or demographic data, 33 (4) a substan- 
tial minority of patients have problems that decrease 
quality of life, especially weakness, leep disturbances, 
and sexual dysfunction (impotence), 36-4° (5) the pre- 
operative perceived quality of life affects the postop- 
erative quality of life and perhaps survival, and (6) 
about 50% regain employment after operation. 
Several of these findings seem to hold for the 
present group of patients evaluated more than 10 
years after transplantation. The trends in the NHP 
scores are in accord with those of a large study by 
Rosenblum and associates, 3s who found that a 
group of transplant recipients with a median age of 
53 years had Sickness Impact Profile scores "similar 
to those of cardiac arrest survivors and postmyocar- 
dial infarct patients." On the other hand, Aravot 
and colleagues 41found much lower NHP scores at a 
mean of 22 months of follow-up in a group of 
patients undergoing transplantation after age 60 
years. It could be that a combination of older age 
and longer postoperative duration correlate with an 
increasing perception of distress. The percentage of
patients employed is similar to that in other reports, 
indicating that there does not appear to be a decline 
of employment with duration after operation. As in 
prior reports, 6 we could find no correlation between 
medical data and perceived quality of life. In the 
future, longitudinal studies (such as those done by 
Jones 33 and Caine 35 and their associates) will permit 
a better assessment of the long-term, time-depen- 
dent trends in these psychosocial nd quality-of-life 
parameters. 
Multivariate analysis of survival. Age at the time 
of transplantation has been cited previously as a 
correlate with survival duration. 1 This result should 
be interpreted with caution, however, because pa- 
tients who received transplant earlier in our experi- 
ence were younger at the time of transplantation 
than were patients who received transplant later in 
our experience. This bias means that relatively more 
right-censoring exists in the survival function of the 
older patients. A second problem with the interpre- 
tation of the age factor is that the instantaneous 
death rate of patients undergoing transplantation at 
older ages (>50 years old) is significantly influenced 
by that of the age-matched nontransplanted popu- 
lation. This means that death beyond this age may 
well not be related to the sequelae of heart trans- 
• plantation. 
The duration of illness before transplantation was 
an intriguing correlate of survival. Evans and asso- 
Table VI. Cox proportional hazards analysis of 
survival 
Normalized t 






Log-likelihood = - 169.9 
Multivariate p = 0.0005 
n = 122 
0.049 0.015 3.26 
0.085 0.024 3.57 
0.721 0.334 2.16 
-0.041 0.016 -2.62 
TXAGE DURILL CMVINF EF12 
Correlation matrix 
TXAGE 1.0 
DURILL 0.08 1.0 
CMVINF 0.08 -0.11 1.0 
EF12 0.14 0.02 -0.09 1.0 
SD, Standard eviation; TXAGE, age at transplantation; DURILL, preop.. 
erative duration of illness; CMVINF, evidence of postoperative CMV 
infection; EF12, ejection fraction 12 months after operation. 
c iates 42 found that higher levels of pretransplanta-- 
tion functional impairment, as measured by the 
Karnofsky index, correlated strongly with poorer 
posttransplantation survival. O'Brien, Buxton, and 
Ferguson 6 found that patients indicating fewer qual.- 
ity-of-life restrictions before transplantation had a 
better likelihood of long-term survival. The degree 
to which preoperative duration of illness correlates 
with these two factors is unclear. However, a rela- 
tionship is suggested by the fact that congestive 
heart failure is usually progressively debilitating. It 
could be that subtle aspects of debilitation resulting 
from cardiac failure are not reversed with cardiac 
transplantation or are perhaps worsened by the 
adverse ffects of immunosuppressive th rapy. 
In a recent study by Elkins and associates, 43
primary or recurrent CMV infection occurred in 
64% of heart transplant recipients a mean of 164 
and median of 84 days after operation. Some of 
the decrease in survival as a result of CMV 
infection can be accounted for by various mani- 
festations of the disease or syndrome. The corre- 
lation of a history of CMV infection with survival 
and with CAD incidence was first noted by Grat- 
tan and colleagues 44in 1989. CMV can regulate 
major histocompatibility complex class I expres- 
sion on smooth muscle cells, 45 and CMV infection 
is associated with progressive intimal thickening 
of intramyocardial rterioles in cardiac grafts. 46 It 
is thus likely that the late effects of CMV infection 
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on survival are due to its contribution to graft 
CAD. This notion is supported by our multivari- 
ate analysis, that is, partly because graft CAD is 
not usually detectable in the first 12 to 24 months 
by conventional angiographic analysis, CMV in- 
fection, and not graft CAD per se, was an inde- 
pendent risk factor for mortality. 
The ejection fraction at 12 months was the fourth 
significant correlate with survival in our analysis. 
This result is not surprising. Myocardial dysfunction 
can result from a variety of causes, such as severe 
recurrent rejection, early graft CAD, myocarditis 
(often viral or drug-induced), cardiomyopathy, or 
"nonspecific" graft failure. In our analysis, ejection 
fraction at 12 months correlated somewhat with 
detection of CAD at 12 months (Pearson coeffi- 
cient = -0.35), but not with diastolic blood pressure 
at 12 months, the total number of episodes of acute 
rejection, or the incidence of all viral infections. 
With respect o the aforementioned multivariate 
analysis, it is important to note the limitations of the 
proportional hazards method. Although it is rela- 
tively easy to apply, it assumes that all covariates will 
have the same shape of hazard function. A more 
versatile approach would determine ach hazard 
function, thus perhaps allowing some understanding 
of the biologic nature of the dependence of the 
covariates in the model. 
The vast majority of this group of patients under- 
went operation in an era when many of the im- 
proved methods of patient management ow in use 
were unavailable, such as cyclosporine, "steroid- 
free" maintenance immunosuppression, specific 
anti-T cell induction immunosuppression, routine 
early antibiotic prophylaxis against CMV (ganciclo- 
vir) and Pneumocystis carinii (trimethoprim/sulfa- 
methoxazole), third-generation a tibiotics, early use 
of prophylactic alcium channel blockade (dilti- 
azem) for reduction of graft CAD progression, 47
improved donor selection, and other empiric fea- 
tures gained from acceleration of experience in 
cardiac transplantation worldwide after about 1983. 
Thus the conclusions we have drawn from our study 
are likely to be unique to this group. 
Conclusions. Results of this study of long-term 
survivors of heart transplantation support the fol- 
lowing conclusions: (1) graft function is well-pre- 
served into the second decade after transplantation, 
(2) exercise capacity is 80% to 90% of that of the 
age-matched general population, (3) patient-per- 
ceived health and well-being (by NHP and GWI3 
examinations) is close to that of the age- and 
sex-matched general population, (4) the cumulative 
incidence of graft CAD is similar to that of the 
cardiac transplant population as a whole, continues 
to develop after 10 years, and is a significant source 
of mortality, and (5) long-term survival is correlated 
with four factors that can be evaluated by 1 year 
after transplantation; younger age at time of trans- 
plantation, shorter preoperative duration of illness, 
absence of postoperative CMV infection, and larger 
left ventricular ejection fraction at 1 year after 
operation. 
Cardiac transplantation can provide patients with 
end-stage cardiac failure an acceptable general medi- 
cal condition, functional status, and perceived quality 
of life well into the second decade after operation. 
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Discuss ion 
Dr. Alfredo Trento (Malibu, Calif.). The importance of 
this review is not in the comparison between different 
groups of patients undergoing transplantation. These 
were groups of patients who received transplantation i  
different periods of time when there were different immu- 
nosuppressive r gimens and in which there were very 
different understandings about the side effects of immu- 
nosuppression therapy and about how to prevent the side 
effects. The conclusions are extremely important and are 
those that we transplant surgeons have been expecting. 
The conclusions are that the quality of the life for the 
surviving patients is similar to that of an age-matched 
population and that the main cause of late death beyond 
10 years after t ansplantation is CAD. CAD is progressive 
to the point that if we wait long enough every transplant 
recipient would be affected. The other conclusion is that 
rejection and CAD together are the main cause of death 
in the patients who died within 10 years of transplantation. 
This brings me to my first question. In the manuscript the 
authors reported that only 15% of the patients are flee of 
rejection 6 months after transplantation. I reviewed our 
experience and found that at 1 year after transplantation 
60% of the patients are flee of rejection and 60% of them 
have also been weaned from steroids. Can you clarify this 
high prevalence of rejection, and do you think that played 
a role in the long-term survival and in the incidence of 
CAD? 
Dr. DeCampli. I think the important factor here is that 
these patients received transplantation i  a unique inter- 
val of time in which we were on a very steep learning curve 
to understanding how to best manage transplant cases 
preoperatively, immediately postoperatively, and in the 
long term. The patients underwent ransplantation be- 
tween 1970 and 1982. Only a few of them ever received 
cyclosporine. It was probably the absence of cyclosporine, 
and not so much the absence of anti-CD4 induction 
therapy, that accounted forthe high incidence of rejection 
in the first couple of months after operation. I qualify that 
by saying that even with the addition of cyclosporine in the 
modern era and with the addition of OKT3 routinely, 
Stanford's incidence of rejection in the first 6 months is 
still 75% to 80%. That number does differ from yours and 
I cannot, offhand, explain that difference. 
Dr. Trento. The manuscript points out the effect of 
CMV infection on survival: history of postoperative CMV 
infection doubles the risk of death at 6 years after 
transplantation. It is clear now that CMV infection seems 
to trigger some sort of generalized immunologic reactiva- 
tion that may trigger a form of acute or chronic rejection 
that we do not know how to diagnose or to treat. This may 
play a role in the occurrence of CAD. For this reason, we 
have started at our institution an aggressive and also costly 
type of prophylaxis against CMV infection, which involves 
the administration of hyperimmune gamma globulin 
weekly for the first 4 weeks and then intravenous admin- 
istration of ganciclovir for 2 weeks followed by oral 
acyclovir for 3 months. With this regimen we have de- 
creased the incidence of postoperative CMV infection 
from a range of about 35% to 70% as reported in the 
literature and from a range of about 50% reported in this 
paper to 4% in patients who were CMV positive before 
transplantation a d to about 26% in the difficult group of 
patients who were CMV negative before transplantation 
and received a CMV-positive organ. Would you comment 
on this aspect and also basically on the approach that 
Stanford is taking at the present for CMV prophylaxis? 
Dr. DeCampli. Stanford's approach currently is as 
follows. If I designate D as donor and R as recipient and 
D-negative R-negative means that neither was CMV 
positive, then we have no prophylaxis for D-negative 
R-negative situations. In the D-negative R-positive and 
D-positive R-positive situations, we give ganciclovir for 2 
weeks intravenously and for 2 weeks orally for a total of 4 
weeks of therapy. With this regimen we have achieved a
significant reduction, as compared with the results of 
these long-term survivors, in CMV infection in the first 6 
months. Thus the incidence is now approximately 15% 
rather than 50%. In the so-called CMV mismatch group, 
that is, D-positive R-negative, which is the most difficult 
group, we have found no benefit with 4 weeks of ganci- 
clovir therapy. Stanford has empirically extended its eov- 
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erage from 4 to 6 weeks. Stanford has found no particular 
benefit o the use of CMV antiglobulin, in particular in the 
D-positive R-negative group. We have had no early deaths 
from CMV infection in the past 5 years. However, we 
cannot yet make a statement on the effect of any of these 
prophylaxis regimens on the later incidence of graft CAD. 
I am not sure any institution can do that yet. 
Dr. Trento. It is my feeling that any immunosuppression 
based on cyclosporine or cyclosporine analogs has reached 
a plateau and basically we have gotten out of cyclosporine 
everything that cyclosporine can give. Further improve- 
ment in results will probably be only minor unless a 
qualitative change in the immunosuppressive therapy is 
made. Would you like to comment on this last point? 
Dr. DeCampli. If you ask how we can best improve the 
survival of patients undergoing transplantation and if 
you make the assumption that graft CAD is caused by a 
chronic rejection phenomenon, then the answer is more 
selective immunosuppression leading ultimately to what 
is now popularly known as "organ-specific clonal aner- 
gy." One possible way of achieving this is the use of 
total lymphoid irradiation for tolerance induction. The 
manner in which stem cells regenerate after total 
lymphoid irradiation is in a peculiar order that, in fact, 
favors acceptance of a transplanted organ; that is to say, 
suppressor cells seem to recover first after total lym- 
phoid irradiation, blunting the effect of the particular 
lymphoid subset hat acts against he implanted organ. 
Total lymphoid irradiation, in conjunction with the use 
of a new anti-CD4 antibody that actually depletes CD4 
cells (rather than just altering their surface membrane 
structure), is currently being investigated as a combina- 
tion that could give us more tolerance induction and 
organ-specific clonal anergy. Dr. Bruce Reitz is working 
on this problem in the laboratory at Stanford currently 
with primates. 
